查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1224660

CRO 體內腫瘤學市場規模、份額和趨勢分析報告：按適應症（血液癌、實體瘤）、地區、細分市場預測，2023-2030 年

Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report By Indication (Blood Cancer, Solid Tumor), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

CRO體內腫瘤市場的發展與趨勢

根據 Grand View Research, Inc. 的最新報告，全球 CRO 腫瘤體內市場規模預計到 2030 年將達到 23 億美元，從 2023 年到 2030 年的複合年增長率為 8.2%。 研發活動外包的增加、對先進藥物的高需求以及 CRO 對國際標準的採用是推動市場增長的主要因素。

此外，專利到期帶來的競爭加劇、仿製藥的快速增長以及生物仿製藥的引入等壓力促使製藥公司尋求這些組織的支持。 因此，可以預見，在預測期內，以癌症為基礎的體內CRO行業很可能會呈現出利潤豐厚的增長態勢。

技術進步，例如用於市場進入者招募和交流的移動創新、基於網絡的生命科學實驗室以及執行常規測試的機器人實驗室，可以帶來市場機會。 在全球範圍內，外包是希望進入新市場的讚助商和製藥公司的一種解決方案。 輝瑞和葛蘭素史克等大型製藥公司已與當地的 CMO 和 CRO 合作，幫助外國公司在新興市場實現其營銷、監管和製造目標，並取得了成功。

此外，該行業不斷增加的合併和合作預計將在未來幾年擴大市場。 例如，2023 年 1 月，分析解決方案公司 Bruker 收購了總部位於瑞士的 CRO Biogenesis，以擴大其在臨床前活動方面的能力。

CRO 體內腫瘤市場報告亮點

實體癌領域在 2022 年佔了 46.9% 的重要收入份額。 全球範圍內癌症發病率的上升以及 WHO 等全球組織對分析其患病率、致病因子和治療方案的興趣日益濃厚，這些都在推動研究和開發。

在基於實體瘤的模型中，患者來源的異種移植物預計在預測期內實現最快的複合年增長率 8.9%。

到 2022 年，北美將佔 49.6% 的最大份額，由於該地區可獲得的資金前景看好，美國將做出重大貢獻。 這刺激了研究活動。 大型製藥和生命科學公司憑藉其在該地區的穩固地位繼續推動市場增長。

亞太地區預計在預測期內實現最快的複合年增長率。 這是因為許多新興國家正在亞太地區投資，監管機構正在根據全球平台進行各種修改以改變臨床試驗評估標準。

內容

第一章研究方法論

  • 市場細分和範圍
    • 區域範圍
  • 調查方法
  • 信息採購
    • 購買的數據庫
    • GVR 內部數據庫
    • 次要信息
    • 初步調查
    • 初步調查的內容
  • 信息或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 模型詳細信息
    • 商品流分析（模型 1）
    • 批量價格分析（模型 2）
  • 二級信息列表
  • 主要信息列表
  • 縮寫列表
  • 目的

第 2 章執行摘要

  • 市場展望

第 3 章 CRO 體內腫瘤市場：變量、趨勢和範圍

  • 細分市場展望
  • 市場動態
    • 市場驅動因素分析
      • 縮短上市時間
      • 經濟效率
      • 增加合併與協作
      • 增加研發活動的外包
    • 市場製約因素分析
      • CRO 質量問題
      • 存在合適的替代品
  • 腫瘤學體內 CRO 市場分析工具
    • 波特的五力分析
    • PESTEL 分析

第 4 章 CRO 中的體內腫瘤市場：適應症估計和趨勢分析

  • 基於腫瘤的體內 CRO 市場：適應症波動分析
  • 血癌
  • 實體瘤
  • 其他

第 5 章 CRO 體內腫瘤市場：估計和趨勢分析

  • 2022 年和 2030 年各地區基於腫瘤的體內 CRO 市場份額
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 意大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 墨西哥
  • 多邊環境協定
    • 南非
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 科威特

第六章競爭格局

  • 戰略框架
  • 公司簡介
    • 查爾斯河實驗室 (CRL)
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • ICON 有限公司
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • Thermo Fisher Scientific Inc.
      • 公司簡介
      • 財務業績
      • 服務基準
      • 戰略舉措
    • 歐陸科學
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • Taconic 生物科學
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 中冠生物科學
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 實驗室公司
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 藥明康德
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • EVOTEC
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 傑克遜實驗室
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
Product Code: GVR-1-68038-859-6

Oncology Based In-vivo CRO Market Growth & Trends:

The global oncology based in-vivo CRO market size is expected to reach USD 2.3 billion by 2030 and is expected to expand at 8.2% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. Increase in outsourcing of R&D activities, high demand for advanced medicines and implementation of international standards by CROs are key factors driving the market growth.

Furthermore, the pressure from the increasing competition due to patent expirations, the rapid growth of generics, and the introduction of biosimilar equivalents are propelling the pharmaceutical companies to take the aid of such organizations. Hence, it can be predicted that the oncology-based in-vivo CRO industry may witness lucrative growth over the forecast period.

Technological advancements such as mobile-enabled innovations for recruiting and communicating with participants, web-based life science labs and robotics labs to perform routine tests can be the opportunities of the market. At a global level, outsourcing is one of the solutions for sponsors and pharma companies seeking to make an entry into a new market. Big pharma companies such as Pfizer and GlaxoSmithKline partner with local CMOs and CROs which has proven to be successful in enabling foreign companies to achieve marketing, regulatory, and manufacturing goals in emerging economies.

Furthermore, an increase in the number of mergers and collaborations in this industry is expected to expand the market in the coming years. For instance, in January 2023, Bruker an analytical solutions company acquired a preclinical Switzerland-based CRO Biogenesis to expand its capabilities in preclinical activities.

Oncology Based In-vivo CRO Market Report Highlights:

  • Solid tumors segment accounted for a significant revenue share of 46.9% in 2022. The increasing incidence of cancer across the globe and the growing interest of world agencies such as the WHO in analyzing their prevalence, causative agents, and treatment options is boosting R&D
  • Based on solid tumor-based model, patient-derived xenograft is anticipated to register the fastest CAGR of 8.9% during the forecast period
  • North America accounted for the largest share of 49.6% in 2022, with the major contributions from the U.S., thanks to promising funding available in the region. This has boosted the research activities. Major pharmaceutical and life sciences companies continue to drive market growth with their established presence in the region
  • Asia Pacific is anticipated to register the fastest CAGR growth during the forecast period, owing to many developed countries investing in Asia Pacific regions and owing to the various amendments made by the regulatory market to change the clinical trials evaluation standards according to the global platform

Table of Content

Chapter 1 Research Methodology

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Regional Scope
    • 1.1.2 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
    • 1.6.2 Volume Price Analysis (Model 2)
  • 1.7 List of Secondary Sources
  • 1.8 List of Primary Sources
  • 1.9 List of Abbreviations
  • 1.10 Objectives

Chapter 2 Executive Summary

  • 2.1 Market Outlook

Chapter 3 Oncology-Based In-vivo CRO Market: Variables, Trends, & Scope

  • 3.1 Segment Outlook
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Accelerating the time to market
      • 3.2.1.2 Economic efficiency
      • 3.2.1.3 Increasing mergers and collaborations
      • 3.2.1.4 Increasing outsourcing of R&D Activities
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 Quality issues with CRO
      • 3.2.2.2 Presence of suitable alternative
  • 3.3 Oncology In-vivo CRO Market Analysis Tools
    • 3.3.1 Porter's Five Forces Analysis
    • 3.3.2 PESTEL Analysis

Chapter 4 Oncology-Based in-vivo CRO Market: Indication Estimates & Trend Analysis

  • 4.1 Oncology-Based in-vivo CRO Market: Indication Movement Analysis
  • 4.2 Blood cancer
    • 4.2.1 Blood cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.1 Syngeneic model based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.2 PDX-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.3 Xenograft-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3 Solid tumors
    • 4.3.1 Solid tumors market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.1 Syngeneic model based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.2 PDX-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.3 Xenograft-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4 Others
    • 4.4.1 Other market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.1 Syngeneic model based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.2 PDX-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.3 Xenograft-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5 Oncology-Based in-vivo CRO Market: Regional Estimates & Trend Analysis, by Indication

  • 5.1 Oncology-Based in-vivo CRO Market Share by Region, 2022 & 2030
  • 5.2 North America
    • 5.2.1 North America Oncology-Based in-vivo CRO market estimates and forecasts, 2018 - 2030
    • 5.2.2 U.S.
      • 5.2.2.1 U.S. Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.2.3 Canada
      • 5.2.3.1 Canada Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
  • 5.3 Europe
    • 5.3.1 Europe Oncology-Based in-vivo CRO market estimates and forecasts, 2018 - 2030
    • 5.3.2 U.K.
      • 5.3.2.1 U.K. Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.3.3 Germany
      • 5.3.3.1 Germany Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.3.4 France
      • 5.3.4.1 France Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.3.5 Italy
      • 5.3.5.1 Italy Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.3.6 Spain
      • 5.3.6.1 Spain Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.3.7 Norway
      • 5.3.7.1 Norway Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.3.8 Sweden
      • 5.3.8.1 Sweden Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.3.9 Denmark
      • 5.3.9.1 Denmark Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Oncology-Based in-vivo CRO market estimates and forecasts, 2018 - 2030
    • 5.4.2 Japan
      • 5.4.2.1 Japan Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.4.3 China
      • 5.4.3.1 China Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.4.4 India
      • 5.4.4.1 India Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.4.5 Australia
      • 5.4.5.1 Australia Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.4.6 Thailand
      • 5.4.6.1 Thailand Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.4.7 South Korea
      • 5.4.7.1 South Korea Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
  • 5.5 Latin America
    • 5.5.1 Latin America Oncology-Based in-vivo CRO market estimates and forecasts, 2018 - 2030
    • 5.5.2 Brazil
      • 5.5.2.1 Brazil Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.5.3 Argentina
      • 5.5.3.1 Argentina Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.5.4 Mexico
      • 5.5.4.1 Mexico Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
  • 5.6 MEA
    • 5.6.1 MEA Oncology-Based in-vivo CRO market estimates and forecasts, 2018 - 2030
    • 5.6.2 South Africa
      • 5.6.2.1 South Africa Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.6.3 Saudi Arabia
      • 5.6.3.1 Saudi Arabia Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.6.4 UAE
      • 5.6.4.1 UAE Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.6.5 Kuwait
      • 5.6.5.1 Kuwait Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)

Chapter 6 Competitive Landscape

  • 6.1 Strategy Framework
  • 6.2 Company Profiles
    • 6.2.1 Charles River Laboratory (CRL)
      • 6.2.1.1 Company overview
      • 6.2.1.2 Financial performance
      • 6.2.1.3 Product benchmarking
      • 6.2.1.4 Strategic initiatives
    • 6.2.2 ICON Plc
      • 6.2.2.1 Company overview
      • 6.2.2.2 Financial performance
      • 6.2.2.3 Product benchmarking
      • 6.2.2.4 Strategic initiatives
    • 6.2.3 Thermo Fisher Scientific Inc.
      • 6.2.3.1 Company overview
      • 6.2.3.2 Financial performance
      • 6.2.3.3 Service benchmarking
      • 6.2.3.4 Strategic initiatives
    • 6.2.4 Eurofins Scientific
      • 6.2.4.1 Company overview
      • 6.2.4.2 Financial performance
      • 6.2.4.3 Product benchmarking
      • 6.2.4.4 Strategic initiatives
    • 6.2.5 Taconic Biosciences
      • 6.2.5.1 Company overview
      • 6.2.5.2 Financial performance
      • 6.2.5.4 Product benchmarking
      • 6.2.5.5 Strategic initiatives
    • 6.2.6 Crown Bioscience
      • 6.2.6.1 Company overview
      • 6.2.6.2 Financial performance
      • 6.2.6.3 Product benchmarking
      • 6.2.6.4 Strategic initiatives
    • 6.2.7 Lab Corp
      • 6.2.7.1 Company overview
      • 6.2.7.2 Financial performance
      • 6.2.7.3 Product benchmarking
      • 6.2.7.4 Strategic initiatives
    • 6.2.8 WuXi AppTec
      • 6.2.8.1 Company overview
      • 6.2.8.2 Financial performance
      • 6.2.8.4 Product benchmarking
      • 6.2.8.5 Strategic Initiatives
    • 6.2.9 EVOTEC
      • 6.2.9.1 Company overview
      • 6.2.9.2 Financial performance
      • 6.2.9.3 Product benchmarking
      • 6.2.9.4 Strategic initiatives
    • 6.2.10 The Jackson Laboratory
      • 6.2.10.1 Company overview
      • 6.2.10.2 Financial performance
      • 6.2.10.4 Product benchmarking
      • 6.2.10.5 Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations

List of Figures

  • Fig. 1 Market summary
  • Fig. 2 Market trends & outlook
  • Fig. 3 Market segmentation & scope
  • Fig. 4 Market driver relevance analysis (Current & future impact)
  • Fig. 5 Pharmaceutical R&D spending, 2007 - 2012 (USD Billion)
  • Fig. 6 Market restraint relevance analysis (Current & future impact)
  • Fig. 7 Penetration & growth prospect mapping
  • Fig. 8 SWOT Analysis, By Factor (political & legal, economic and social)
  • Fig. 9 Porter's Five Forces Analysis
  • Fig. 10 Oncology-Based in-vivo CRO market indication outlook key takeaways
  • Fig. 11 Oncology-Based in-vivo CRO market: Indication movement analysis
  • Fig. 12 Global blood cancer market, 2018 - 2030 (USD Million)
  • Fig. 13 Global syngeneic model-based blood cancer market, 2018 - 2030 (USD Million)
  • Fig. 14 Global PDX model-based blood cancer market, 2018 - 2030 (USD Million)
  • Fig. 15 Global xenograft-based blood cancer market, 2018 - 2030 (USD Million)
  • Fig. 16 Global solid tumor market, 2018 - 2030 (USD Million)
  • Fig. 17 Global syngeneic model-based solid tumor market, 2018 - 2030 (USD Million)
  • Fig. 18 Global PDX model-based solid tumor market, 2018 - 2030 (USD Million)
  • Fig. 19 Global xenograft-based solid tumor market, 2018 - 2030 (USD Million)
  • Fig. 20 Global other cancers market, 2018 - 2030 (USD Million)
  • Fig. 21 Global syngeneic model-based other cancers market, 2018 - 2030 (USD Million)
  • Fig. 22 Global PDX model-based other cancers market, 2018 - 2030 (USD Million)
  • Fig. 23 Global xenograft-based other cancers market, 2018 - 2030 (USD Million)
  • Fig. 24 Regional marketplace: Key takeaways
  • Fig. 25 Regional outlook, 2022 & 2030
  • Fig. 26 North America Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 28 Canada Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 29 Europe in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 30 U.K. Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 31 Germany Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 32 France Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 33 Italy Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 34 Spain Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 35 Norway Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 36 Sweden Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 37 Denmark Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 38 Asia Pacific Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 39 Japan oncology-based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 40 China oncology-based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 41 India Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 42 Australia Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 43 Thailand Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 44 South Korea Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 45 Latin America Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 46 Brazil Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 47 Argentina Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 48 Mexico Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 49 MEA Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 50 South Africa Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 51 Saudi Arabia Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 52 UAE Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 53 Kuwait Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)